Drugs / GLP-1
GLP-1
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00992901 | Oct 2009 → Aug 2026 overdue | hypoglycemia, postgastrectomy syndrome | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 15 trials · 1 met primary | ||||||
| Phase 1 | NCT02550548 | Apr 2016 → Apr 2021 | acute insulin response | David D'Alessio, M.D. | Completed | No outcome recorded |
| Phase 1 | NCT01795144 | Jan 2014 → Mar 2017 | monogenic diabetes | University of Chicago | Completed | No outcome recorded |
| Phase 1 | NCT02731664 | Sep 2012 → Aug 2017 | — | Uppsala University | Completed | Met primary |
| Phase 1 | NCT00393445 | Nov 2006 → May 2007 | hyperglycemia | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 1 | NCT00468884 | Oct 2006 → Feb 2007 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT02127996 | Mar 2015 → Mar 2017 | coronary artery disorder, myocardial infarction | Papworth Hospital NHS Foundation Trust | Unknown | Missed primary |
| Phase 2 | NCT00686972 | May 2007 → Oct 2010 | — | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01607450 | May 2010 → Dec 2012 | type 2 diabetes mellitus | Indiana University | Completed | No outcome recorded |
| Phase not applicable10 trials | ||||||
| — | NCT07398300 | Mar 2026 → Mar 2027 expected | type 2 diabetes mellitus | Rigshospitalet, Denmark | Recruiting | No outcome recorded |
| — | NCT02370745 | Nov 2014 → Mar 2018 | muscular atrophy | University of Nottingham | Completed | No outcome recorded |
| — | NCT01851694 | May 2013 → Dec 2026 expected | cystic fibrosis, exocrine pancreatic insufficiency | University of Pennsylvania | Recruiting | No outcome recorded |
| — | NCT01760772 | Feb 2013 → Feb 2015 | heart disorder | David Dalessio | Unknown | No outcome recorded |
| — | NCT01749163 | Sep 2012 → Dec 2013 | hyperproglucagonemia | Rigshospitalet, Denmark | Completed | No outcome recorded |
| — | NCT00940134 | Mar 2011 → Jan 2012 | obesity disorder | University of Copenhagen | Completed | No outcome recorded |
| — | NCT00869102 | May 2009 → Dec 2010 | diabetes mellitus, metabolic syndrome X | University Hospital Tuebingen | Withdrawn | No outcome recorded |
| — | NCT00856700 | Nov 2008 → Jun 2012 | metabolic syndrome X | University of Rome Tor Vergata | Completed | No outcome recorded |
| — | NCT01176890 | Jul 2008 → Aug 2011 | — | University Hospital, Gentofte, Copenhagen | Unknown | No outcome recorded |
| — | NCT00588380 | Nov 2007 → Sep 2010 | diabetes mellitus | Mayo Clinic | Completed | No outcome recorded |
| Comparator or background therapy11 trials | ||||||
| Phase 0 | NCT04133922 Comparator | Oct 2019 → Oct 2023 | type 1 diabetes mellitus | University of Virginia | Withdrawn | No outcome recorded |
| Phase 0 | NCT02130778 Comparator | Apr 2014 → Oct 2015 | — | Clinical Hospital Centre Zagreb | Completed | No outcome recorded |
| Phase 1 | NCT01880827 Comparator | Jan 2013 → Nov 2015 | obesity disorder, type 2 diabetes mellitus | Turku University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT00822003 Comparator | Feb → Jun 2008 | glucose metabolism disease | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT02192853 Background | May 2013 → Feb 2014 | type 2 diabetes mellitus | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| Phase 4 | NCT00859079 Comparator | Jun → Dec 2006 | hyperglycemia, type 2 diabetes mellitus | Medical University of Graz | Completed | No outcome recorded |
| — | NCT06194955 Comparator | Jan 2023 → Dec 2025 | hyperproglucagonemia | University of Copenhagen | Completed | No outcome recorded |
| — | NCT03414333 Comparator | Jun 2016 → Jun 2017 | cerebral degeneration, glucose metabolism disease, obesity disorder | University of Pisa | Completed | No outcome recorded |
| — | NCT01677104 Comparator | Aug 2012 → Jul 2014 | obesity disorder, type 2 diabetes mellitus | Katarina Kos | Completed | No outcome recorded |
| — | NCT01347801 Comparator | Mar 2011 → Sep 2014 | hypoglycemia | Rigshospitalet, Denmark | Completed | No outcome recorded |
| — | NCT00264199 Comparator | Dec 2005 → Dec 2007 | congestive heart failure | Aarhus University Hospital Skejby | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-09-16 | Biomea Fusion Inc. | Results Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update biomeafusion.com ↗
In a rodent model of T2D, icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with preservation of lean mass, outperforming the group given semaglutide alone. |
| 2013-07-26 | Merck Sharp & Dohme LLC | Regulatory Merck Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin merck.com ↗
Investigation into GLP-1 based diabetes therapies concluded: No new concerns for GLP-1 therapies identified on the basis of available evidence. |
All press releases naming this drug 5 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 35 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLP-1 | “i.v. GLP-1 infusion” NCT02192853 ↗ |
| Known as | 7-36 amide | “Subjects received GLP-1 (7-36 amide) or saline infusions during and after a standardized liquid mixed meal” PMID 23599045 ↗ Apr 2013 |
| Known as | GLP-1(7-36)amide | “GLP-1(7-36)amide” NCT00393445 ↗ |
| Known as | glucagon-like peptide (GLP)-1 | “Previous studies have shown beneficial effects of exogenous glucagon-like peptide (GLP)-1 on glycaemia in critically ill patients, a phenomenon also seen in patients with type...” PMID 26567860 ↗ Nov 2015 |
| Known as | glucagon-like peptide-1 | “Intravenous infusion of glucagon-like peptide-1 (GLP-1) consisting of a priming dose of 4.5 pmol/kg/min for 10 minutes followed by a steady-state infusion of 1.5 pmol/kg/min...” NCT07398300 ↗5“Glucagon-like peptide-1 (GLP-1) has many effects on the human body, but its glucose-lowering effect through its stimulation of insulin secretion is the most significant.” PMID 30298444 ↗ Oct 2018 “The incretin hormone glucagon-like peptide 1 (GLP-1), beyond its effects on blood glucose, has beneficial actions on vascular function.” PMID 23069838 ↗ Oct 2012 “The incretin, Glucagon-Like-peptide-1 (GLP-1) will be infused into the veins starting 30 minutes prior to initiating the GPA test.” NCT01851694 ↗ “Glucagon like peptide-1 (GLP-1) promotes satiety and reduces food intake.” NCT00822003 ↗ “GLP-1 (glucagon-like peptide 1, another member of incretin family)” NCT01880827 ↗ |
| Known as | Glucagon-like peptide-1 (GLP-1) | “Glucagon-like peptide-1 (GLP-1)” NCT01795144 ↗ |
| Action | Inhibit | “GLP-1 and ROSE-010 inhibit postprandial gastrointestinal motility through GLP-1R at myenteric neurons, involving nitrergic and cyclic adenosine monophosphate-dependent mechanisms.” PMID 29177486 ↗ Feb 2018 |
| Modality | Peptide | “GLP-1 is a naturally occurring peptide hormone” NCT00264199 ↗ |
| Route | Intravenous | “48 hours of treatment with intravenous GLP-1 compared to placebo” NCT00264199 ↗ |
| Target | GLP1R | “The GLP-1 receptor (GLP1R) is the principal site of action of GLP-1” NCT00588380 ↗ |